Fact CheckerSign in

NCT07240987Not yet recruitingPhase 1/2

Mesenchymal Stem Cells for Chronic Kidney Diseases

A Randomized Controlled Study of Mesenchymal Stem Cells in the Treatment of Chronic Kidney Diseases

Source: ClinicalTrials.gov · Last updated 24 Dec 2025

Brief summary (registry, in English)

This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
32 (estimated)
First submitted
17 Nov 2025
Start date
Jan 2026
Primary completion date
Aug 2027
Lead sponsor
The First Affiliated Hospital of Air Force Medical University
NCT number
NCT07240987

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 32
  • From Jan 2026 to the primary completion date, Aug 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Received blood product transfusion therapy within 1 month
  • Pregnant women or women with plans for pregnancy within 3 months after MSC therapy
  • Participation in drug-related clinical trials within the past 2 months

Other illness

  • Autosomal dominant or recessive polycystic kidney disease (ADPKD)
  • History of kidney transplant or other solid organ transplant
  • Active systemic or localized infection (e.g., pneumonia, osteomyelitis)
  • Allergy to stem cells themselves or stem cell-related culture medium
  • History of coagulation disorders (thromboembolism, pulmonary embolism, deep vein thrombosis)
  • History of malignancy or current malignant disease
  • Any form of drug abuse, mental illness, or other conditions considered by the investigator as potentially affecting the trial's validity or the subject's health

Lab values

  • Extremely severe anemia (hemoglobin \< 30 g/L)
  • History of allergic reaction to cell products (e.g., blood transfusion, platelets)

Other

  • Elevated tumor markers (AFP, CEA, CA199, CA125, etc.)

Who the study is looking for

  • Agreement to participate in the trial and provision of signed written informed consent
  • Pathological diagnosis of diabetic nephropathy or hypertensive renal damage
  • 15 ≤ eGFR \< 60 mL/min/1.73m², UACR \> 300 mg/g
  • Age ≥ 18 years

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.